Cargando…

Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study

BACKGROUND: Although liver metastasis occurs in approximately 15% of metastatic non-small cell lung cancer (NSCLC) patients with poor prognosis, its prognostic effect in patients who receive immunotherapy is unclear. This study aimed to verify the effects of liver metastasis on the prognosis of meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Myeong Geun, Choi, Chang-Min, Lee, Dae Ho, Kim, Sang-We, Yoon, Shinkyo, Kim, Woo Sung, Ji, Wonjun, Lee, Jae Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264330/ https://www.ncbi.nlm.nih.gov/pubmed/34295661 http://dx.doi.org/10.21037/tlcr-21-206

Ejemplares similares

Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
por: Hyun, Dong-gon, et al.
Publicado: (2020)

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment
por: Jang, Yoon Jung, et al.
Publicado: (2023)

Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
por: Yoon, Byung Woo, et al.
Publicado: (2019)

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Prognostic Factor and Clinical Outcome in Stage III Non–Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population
por: Kim, Ho Cheol, et al.
Publicado: (2021)

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
por: Cho, Su Han, et al.
Publicado: (2021)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Effect of medical thoracoscopy‐guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non‐small cell lung cancer: A pilot study
por: Choi, Myeong Geun, et al.
Publicado: (2019)

Sex differences in the characteristics and survival of patients with non‐small‐cell lung cancer: A retrospective analytical study based on real‐world clinical data of the Korean population
por: Jeon, Da Som, et al.
Publicado: (2022)

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
por: Won, Sang Eun, et al.
Publicado: (2020)

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States
por: Richter, Joshua, et al.
Publicado: (2023)

Real-world data analysis of patients with cancer of unknown primary
por: Kang, Sora, et al.
Publicado: (2021)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
por: Roh, Yun Hwa, et al.
Publicado: (2023)

Prognosis of multi‐level N2‐positive non‐small cell lung cancer according to lymph node staging using endobronchial ultrasound‐transbronchial biopsy
por: Yoon, Hee‐Young, et al.
Publicado: (2018)

Attacks on the Press: Journalism on the World's Front Lines, 2015 Edition
por: Journalists, Committee
Publicado: (2015)

Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
por: Lee, Ji Young, et al.
Publicado: (2016)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

A Multicenter Study of Real-world Practice for Management of Abnormal Liver Function Tests in Children with Acute Infectious Diseases
por: Lee, Yoon, et al.
Publicado: (2021)

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
por: Park, Kang-Seo, et al.
Publicado: (2018)

Ground Moving Target Tracking Filter Considering Terrain and Kinematics
por: Kim, Do-Un, et al.
Publicado: (2021)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice
por: Oh, Dong Kyu, et al.
Publicado: (2019)

Risk for pneumonia requiring hospitalization or emergency room visit according to delivery device for inhaled corticosteroid/long-acting beta-agonist in patients with chronic airway diseases as real-world evidence
por: Park, Ju-Hee, et al.
Publicado: (2019)

Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non–Small Cell Lung Cancer
por: Yoon, Shinkyo, et al.
Publicado: (2022)

Front Cover
por: Lee, Dagyeong, et al.
Publicado: (2023)

Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR ‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial
por: Kim, Jiwon, et al.
Publicado: (2023)

A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non–Small Cell Lung Cancer
por: Kim, Eo Jin, et al.
Publicado: (2022)

Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
por: Ha, Kyoung Hwa, et al.
Publicado: (2018)

Influence of lesion and disease subsets on the diagnostic performance of the quantitative flow ratio in real-world patients
por: Lee, Kwan Yong, et al.
Publicado: (2021)

Perception and safety analysis of COVID‐19 vaccination in cancer patients: A multicenter, real‐world study
por: Lee, Kyoungmin, et al.
Publicado: (2022)

Surgical resection of metastasis to the pancreas
por: You, Dong Do, et al.
Publicado: (2011)

Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
por: Choi, Min Chul, et al.
Publicado: (2020)

Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer
por: Choi, Myeong Geun, et al.
Publicado: (2020)

Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Lee, Jang Ho, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ine7dkgbfmq63cf8og4lutff6c